Thomas Meier
Fondateur chez SANTHERA PHARMACEUTICALS HOLDING AG
Fortune : 141 664 $ au 30/04/2024
Postes actifs de Thomas Meier
Sociétés | Poste | Début | Fin |
---|---|---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Président | 30/06/2022 | - |
Fondateur | 07/09/2004 | - | |
Directeur/Membre du Conseil | 04/04/2017 | 30/06/2022 | |
Directeur Général | 11/10/2011 | 01/12/2019 | |
Investor Relations Contact | - | - | |
Public Communications Contact | - | - | |
ONCONETIX, INC. | Directeur/Membre du Conseil | 06/02/2024 | - |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Directeur/Membre du Conseil | 01/05/2020 | - |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Corporate Officer/Principal | - | - |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/01/2022 | - |
Historique de carrière de Thomas Meier
Anciens postes connus de Thomas Meier
Sociétés | Poste | Début | Fin |
---|---|---|---|
PharmaBiome AG
PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Président | 01/07/2020 | 01/01/2021 |
MyoContract AG | Directeur Général | 01/01/2000 | 01/01/2004 |
Fondateur | 01/01/2000 | 01/01/2004 |
Formation de Thomas Meier
University of Basel | Doctorate Degree |
Statistiques
Internationale
Suisse | 7 |
Etats-Unis | 3 |
Opérationnelle
Director/Board Member | 4 |
Chairman | 3 |
Founder | 3 |
Sectorielle
Health Technology | 6 |
Consumer Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
ONCONETIX, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
MyoContract AG | Health Technology |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Health Technology |
PharmaBiome AG
PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Commercial Services |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Finance |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Thomas Meier
- Expérience